Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure
Hiroyuki Nakayama, … , Steven R. Houser, Jeffery D. Molkentin
Hiroyuki Nakayama, … , Steven R. Houser, Jeffery D. Molkentin
Published September 4, 2007
Citation Information: J Clin Invest. 2007;117(9):2431-2444. https://doi.org/10.1172/JCI31060.
View: Text | PDF
Research Article Cardiology

Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure

  • Text
  • PDF
Abstract

Loss of cardiac myocytes in heart failure is thought to occur largely through an apoptotic process. Here we show that heart failure can also be precipitated through myocyte necrosis associated with Ca2+ overload. Inducible transgenic mice with enhanced sarcolemmal L-type Ca2+ channel (LTCC) activity showed progressive myocyte necrosis that led to pump dysfunction and premature death, effects that were dramatically enhanced by acute stimulation of β-adrenergic receptors. Enhanced Ca2+ influx–induced cellular necrosis and cardiomyopathy was prevented with either LTCC blockers or β-adrenergic receptor antagonists, demonstrating a proximal relationship among β-adrenergic receptor function, Ca2+ handling, and heart failure progression through necrotic cell loss. Mechanistically, loss of cyclophilin D, a regulator of the mitochondrial permeability transition pore that underpins necrosis, blocked Ca2+ influx–induced necrosis of myocytes, heart failure, and isoproterenol-induced premature death. In contrast, overexpression of the antiapoptotic factor Bcl-2 was ineffective in mitigating heart failure and death associated with excess Ca2+ influx and acute β-adrenergic receptor stimulation. This paradigm of mitochondrial- and necrosis-dependent heart failure was also observed in other mouse models of disease, which supports the concept that heart failure is a pleiotropic disorder that involves not only apoptosis, but also necrotic loss of myocytes in association with dysregulated Ca2+ handling and β-adrenergic receptor signaling.

Authors

Hiroyuki Nakayama, Xiongwen Chen, Christopher P. Baines, Raisa Klevitsky, Xiaoying Zhang, Hongyu Zhang, Naser Jaleel, Balvin H.L. Chua, Timothy E. Hewett, Jeffrey Robbins, Steven R. Houser, Jeffery D. Molkentin

×

Figure 9

Bcl-2 overexpression does not rescue β2a overexpression–dependent disease.

Options: View larger image (or click on image) Download as PowerPoint
Bcl-2 overexpression does not rescue β2a overexpression–dependent diseas...
(A) Gross morphological view of hearts from a Bcl-2 single-transgenic mouse and a mouse with both the Bcl-2 transgene and the β2a double transgenes without Dox (4 months of age). (B–E) Heart weight normalized to body weight (B), fractional shortening assessment (C), histological assessment of cardiac pathology by Masson’s trichrome staining (D), and quantitation of fibrotic area (blue) from trichrome-stained cardiac sections (E) for control tTA single-transgenic mice, DTG mice, Bcl-2 single-transgenic mice, and DTG mice with the Bcl-2 transgene. Numbers indicate the number of mice analyzed in each group (E, 10 photographs each). Original magnification, ×200 (D). *P < 0.05 versus control, ANOVA. (F) Kaplan-Meier curves from DTG mice containing the Bcl-2 transgene infused with Iso at 60 mg/kg/d for 14 days or with PBS. (G) Western blot for Bcl-2 protein from the hearts of control tTA single-transgenic and DTG mice. GAPDH protein levels did not vary between samples (not shown).

Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts